Literature DB >> 30526806

The cost of treatment and its related complications for men who receive surgery or radiation therapy for prostate cancer.

Alaina Garbens1, Christopher J D Wallis1, Rano Matta1, Ronald Kodama1, Sender Herschorn1, Steven Narod2,3, Robert K Nam1.   

Abstract

INTRODUCTION: We sought to examine the costs related to treatment and treatment-related complications for patients treated with surgery or radiation for localized prostate cancer.
METHODS: We performed a population-based, retrospective cohort study of men who underwent open radical prostatectomy or radiation from 2004-2009 in Ontario, Canada. Costs, including initial treatment and inpatient hospitalization, emergency room visit, outpatient consultation, physician billings, and medication costs, were determined for five years following treatment using a validated costing algorithm. Multivariable negative binomial regression was used to assess the association between treatment modality and costs.
RESULTS: A total of 28 849 men underwent treatment for localized prostate cancer from 2004- 2009. In the five years following treatment, men who underwent radiation (n=12 675) had 21% higher total treatment and treatment-related costs than men who underwent surgery ($16 716/person vs. $13 213/person). Based on multivariable analysis, while men who underwent XRT had a lower relative cost in their first year after treatment (relative rate [RR] 0.97; 95% confidence interval [CI] 0.94-1.0; p=0.025), after year 2, annual costs were significantly higher in the radiation group compared to the surgery group (total cost for year 5, RR 1.44; 95% CI 1.17-1.76; p<0.0001). Our results were similar when restricted to young, healthy men and to older men.
CONCLUSIONS: Men who undergo radiation have significantly higher five-year total treatment-related costs compared to men who undergo open radical prostatectomy. While surgery was associated with slightly higher initial costs, radiotherapy had higher costs in subsequent years.

Entities:  

Year:  2018        PMID: 30526806      PMCID: PMC6737732          DOI: 10.5489/cuaj.5598

Source DB:  PubMed          Journal:  Can Urol Assoc J        ISSN: 1911-6470            Impact factor:   1.862


  32 in total

1.  The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies.

Authors:  Erik von Elm; Douglas G Altman; Matthias Egger; Stuart J Pocock; Peter C Gøtzsche; Jan P Vandenbroucke
Journal:  Lancet       Date:  2007-10-20       Impact factor: 79.321

2.  Radiation therapy for prostate cancer increases subsequent risk of bladder and rectal cancer: a population based cohort study.

Authors:  Alan M Nieder; Michael P Porter; Mark S Soloway
Journal:  J Urol       Date:  2008-09-17       Impact factor: 7.450

3.  Long-term medical-care costs related to prostate cancer: estimates from linked SEER-Medicare data.

Authors:  M E Stokes; L Black; A Benedict; C G Roehrborn; P Albertsen
Journal:  Prostate Cancer Prostatic Dis       Date:  2010-03-09       Impact factor: 5.554

4.  A 3-year study of high-cost users of health care.

Authors:  Walter P Wodchis; Peter C Austin; David A Henry
Journal:  CMAJ       Date:  2016-01-11       Impact factor: 8.262

5.  Incidence of complications other than urinary incontinence or erectile dysfunction after radical prostatectomy or radiotherapy for prostate cancer: a population-based cohort study.

Authors:  Robert K Nam; Patrick Cheung; Sender Herschorn; Refik Saskin; Jiandong Su; Laurence H Klotz; Michelle Chang; Girish S Kulkarni; Yuna Lee; Ronald T Kodama; Steven A Narod
Journal:  Lancet Oncol       Date:  2014-01-17       Impact factor: 41.316

6.  Urinary Diversion for Severe Urinary Adverse Events of Prostate Radiation: Results from a Multi-Institutional Study.

Authors:  Mitchell R Bassett; Yahir Santiago-Lastra; John T Stoffel; Robert Goldfarb; Sean P Elliott; Scott C Pate; Joshua A Broghammer; Thomas Gaither; Benjamin N Breyer; Alex J Vanni; Bryan B Voelzke; Bradley A Erickson; Christopher D McClung; Angela P Presson; Jonathan D Tward; Jeremy B Myers
Journal:  J Urol       Date:  2016-11-01       Impact factor: 7.450

7.  Complications after radical prostatectomy or radiotherapy for prostate cancer: results of a population-based, propensity score-matched analysis.

Authors:  Christopher J D Wallis; Sender Herschorn; Refik Saskin; Jiandong Su; Laurence H Klotz; Michelle Chang; Girish S Kulkarni; Yuna Lee; Ronald T Kodama; Steven A Narod; Robert K Nam
Journal:  Urology       Date:  2015-03       Impact factor: 2.649

8.  Health care costs for state transition models in prostate cancer.

Authors:  Murray D Krahn; Karen E Bremner; Brandon Zagorski; Shabbir M H Alibhai; Wendong Chen; George Tomlinson; Nicholas Mitsakakis; Gary Naglie
Journal:  Med Decis Making       Date:  2013-07-26       Impact factor: 2.583

Review 9.  Second malignancies after radiotherapy for prostate cancer: systematic review and meta-analysis.

Authors:  Christopher J D Wallis; Alyson L Mahar; Richard Choo; Sender Herschorn; Ronald T Kodama; Prakesh S Shah; Cyril Danjoux; Steven A Narod; Robert K Nam
Journal:  BMJ       Date:  2016-03-02

10.  Prostatectomy versus radiotherapy for early-stage prostate cancer (PREPaRE) study: protocol for a mixed-methods study of treatment decision-making in men with localised prostate cancer.

Authors:  Allan Ben Smith; Pascal Mancuso; Mark Sidhom; Karen Wong; Megan Berry; Orlando Rincones; Dion Forstner; Lesley Bokey; Afaf Girgis
Journal:  BMJ Open       Date:  2017-11-03       Impact factor: 2.692

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.